Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Avastin To Zevalin: ODAC’s Most Memorable Moments

Executive Summary

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

You may also be interested in...



ODAC Veterans Disagree On Value Of Public Hearing At Panel Meetings

Current and former chairs of FDA’s Oncologic Drugs Advisory Committee debate the usefulness of the public hearing and its impact on committee deliberations.

Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints

Rather than damaging the use of progression-free survival as an endpoint in oncology clinical trials, as some have feared, the battle over Avastin’s (bevacizumab) metastatic breast cancer claim could give sponsors some clarity as to how FDA expects the magnitude of PFS benefit to be defined.

Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"

Tempers frayed as the FDA Oncologic Drugs Advisory Committee gathered to review GlaxoSmithKline's Avodart (dutasteride) and Merck's Proscar (finasteride) for prostate cancer prevention Dec. 1.

Related Content

Topics

UsernamePublicRestriction

Register

PS055288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel